Genetic variation associated with euphorigenic effects of d-amphetamine is associated with diminished risk for schizophrenia and attention deficit hyperactivity disorder

Here, we extended our findings from a genome-wide association study of the euphoric response to d-amphetamine in healthy human volunteers by identifying enrichment between SNPs associated with response to d-amphetamine and SNPs associated with psychiatric disorders. We found that SNPs nominally asso...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Proceedings of the National Academy of Sciences - PNAS 2014-04, Vol.111 (16), p.5968-5973
Hauptverfasser:	Hart, Amy B., Gamazon, Eric R., Engelhardt, Barbara E., Sklar, Pamela, Kähler, Anna K., Hultman, Christina M., Sullivan, Patrick F., Neale, Benjamin M., Faraone, Stephen V., de Wit, Harriet, Cox, Nancy J., Palmer, Abraham A.
Format:	Artikel
Sprache:	eng
Schlagworte:	agonists Alcohols Alleles antagonists Attention Deficit Disorder with Hyperactivity - drug therapy Attention Deficit Disorder with Hyperactivity - genetics Attention Deficit Hyperactivity Disorder Biological Sciences Bipolar disorder Bipolar Disorder - drug therapy Bipolar Disorder - genetics Datasets Dextroamphetamine - pharmacology Dextroamphetamine - therapeutic use Disorders drugs Effects Euphoria - drug effects Genetic Predisposition to Disease Genetic Variation Genetics genome-wide association study Genomes Humans inflammatory bowel disease Medical genetics Parkinson disease Phenotype Phenotypes Polymorphism, Single Nucleotide - genetics Protective Agents - pharmacology Protective Agents - therapeutic use Reproducibility of Results risk Risk Factors Schizophrenia Schizophrenia - drug therapy Schizophrenia - genetics single nucleotide polymorphism volunteers
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!